Why the study?
Clinical application of Ang-(1-7) is limited by unfavorable pharmacological properties, prompting the evaluation of engineered probiotic-based delivery to attenuate diabetic retinopathy.
Does oral administration of Lactobacillus paracasei secreting Ang-(1-7) prevent diabetic retinopathy in diabetic mouse models?
Does oral administration of Lactobacillus paracasei secreting Ang-(1-7) prevent diabetic retinopathy in diabetic mouse models?
Answers are grounded in this paper and cite their sources.
Probiotics-based delivery of Ang-(1-7) using engineered Lactobacillus paracasei attenuates diabetic retinopathy in mouse models, offering a potential novel therapeutic approach.
Purpose: A multitude of animal studies substantiates the beneficial effects of Ang-(1–7), a peptide hormone in the protective axis of the renin angiotensin system, in diabetes and its associated complications including diabetic retinopathy (DR). However, the clinical application of Ang-(1–7) is limited due to unfavorable pharmacological properties. As emerging evidence implicates gut dysbiosis in pathogenesis of diabetes and supports beneficial effects of probiotics, we sought to develop probiotics-based expression and delivery system to enhance Ang-(1–7) and evaluate the efficacy of engineered probiotics expressing Ang-(1–7) in attenuation of DR in animal models. Methods: Ang-(1–7) was expressed in the Lactobacillus species as a secreted fusion protein with a trans-epithelial carrier to allow uptake into circulation. To evaluate the effects of Ang-(1–7) expressed from Lactobacillus paracasei (LP), adult diabetic eNOS−/− and Akita mice were orally gavaged with either 1 × 109 CFU of LP secreting Ang-(1–7) (LP-A), LP alone or vehicle, 3 times/week, for 8 and 12 weeks, respectively. Results: Ang-(1–7) is efficiently expressed from different Lactobacillus species and secreted into circulation in mice fed with LP-A. Oral administration of LP-A significantly reduced diabetes-induced loss of retinal vascular capillaries. LP-A treatment also prevented loss of retinal ganglion cells, and significantly decreased retinal inflammatory cytokine expression in both diabetic eNOS−/− and Akita mice. Conclusions: These results provide proof-of-concept for feasibility and efficacy of using engineered probiotic species as live vector for delivery of Ang-(1–7) with enhanced bioavailability. Translational Relevance: Probiotics-based delivery of Ang-(1–7) may hold important therapeutic potential for the treatment of DR and other diabetic complications.
No takes yet. Share an insight, caveat, or question.
Verma et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: